Otsuka heads fda ionis partnered als drug hits primary phase 3 endpoint

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 24 Sept, 12:07 UTC

A phase 3 study of Otsuka and Ionis Pharmaceuticals’ amyotrophic lateral sclerosis drug candidate has hit its primary endpoint, positioning the partners to talk to regulators about expedited approvals.

policyscience

Sources

• T2Otsuka heads fda ionis partnered als drug hits primary phase 3 endpointFierce Biotech / Fierce Healthcare / MedCity / GEN24 Sept, 12:07